Summary - Fundamenty - Všechna data pro vaši analýzu

Nástroje

Akciový screener

Kalendář zisků

Super investoři

Ostatní

Návod

IČ: 19940963

5. května 521, 501 01 Turnov

Zásady GDPR

Podmínky služby

Všechna práva vyhrazena @ 2024, Fundamenty.cz

Proudly created by draftspot.net

Madrigal Pharmaceuticals, Inc.

MDGL

Valuace

Růst

Zdraví

Cena

$ 530.56

+5.80 (1.17%)

Kapitalizace

10.8B

Obrat

Zisk

Aktiva

Dluh

ROE

ROA

-37

Cena 1R

265-615

⌀ Cena

402.97

Dividenda

0.0(0.0%)

Čtvrtletní 10-Q

Celoroční 10-K

Nadcházející oznámení zisků

Poslední dividenda

Profil

Madrigal Pharmaceuticals, Inc., biofarmaceutická společnost v klinickém stadiu, se zaměřuje na vývoj a komercializaci léčebných kandidátů pro léčbu kardiovaskulárních, metabolických a jaterních onemocnění. Jeho hlavní kandidátskou látkou je resmetirom, jaterně řízený selektivní agonista-ß receptorů thyreoidálního hormonu, který se nachází v klinických studiích fáze III pro léčbu nealkoholické steatohepatitidy. Společnost také vyvíjí MGL-3745, záložní sloučeninu pro resmetirom. Má dohodu o výzkumu, vývoji a komercializaci s Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. má sídlo ve West Conshohocken v Pensylvánii.

Sektor

Healthcare

Odvětví

Biotechnology

Počet zaměstnanců

528

Založení

2007-02-06

Adresa

Four Tower Bridge

CEO

William J. Sibold

Web

www.madrigalpharma.com

Podobné společnosti

RNA

Avidity Biosciences, Inc.

$ 69.78

- $ 0.06

JAZZ

Jazz Pharmaceuticals plc

$ 132.79

+ $ 1.63

MRNA

Moderna, Inc.

$ 23.89

- $ 0.66

RYTM

Rhythm Pharmaceuticals, Inc.

$ 96.93

- $ 3.37

TECH

Bio-Techne Corporation

$ 57.36

- $ 0.05

EXEL

Exelixis, Inc.

$ 40.25

- $ 0.56

BMRN

BioMarin Pharmaceutical Inc.

$ 52.17

+ $ 0.71

Zahraniční články

Assenagon Asset Management S.A. Acquires New Stake in Madrigal Pharmaceuticals, Inc. $MDGL

3:17 30-03-2026

Assenagon Asset Management S.A. purchased a new position in shares of Madrigal Pharmaceuticals, Inc....

Madrigal (MDGL) Surges 12.3%: Is This an Indication of Further Gains?

10:06 27-03-2026

Madrigal (MDGL) saw its shares surge in the last session with trading volume being higher than avera...

Madrigal Pharmaceuticals (NASDAQ:MDGL) versus SciSparc (NASDAQ:SPRC) Financial Review

1:16 20-03-2026

Madrigal Pharmaceuticals (NASDAQ: MDGL - Get Free Report) and SciSparc (NASDAQ: SPRC - Get Free Repo...

2,600 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Bought by Bamco Inc. NY

3:36 17-03-2026

Bamco Inc. NY bought a new position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) in th...

Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by ArrowMark Colorado Holdings LLC

5:34 15-03-2026

ArrowMark Colorado Holdings LLC lowered its position in shares of Madrigal Pharmaceuticals, Inc. (NA...

32,662 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Bought by Ally Bridge Group NY LLC

4:02 15-03-2026

Ally Bridge Group NY LLC bought a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) during ...

120,000 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Purchased by Alkeon Capital Management LLC

3:28 15-03-2026

Alkeon Capital Management LLC bought a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) du...

Barclays PLC Cuts Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL

3:59 12-03-2026

Barclays PLC lowered its position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) by 20.4...

Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down

11:01 20-02-2026

MDGL swings to a wider Q4 loss as expenses surge, but Rezdiffra sales top estimates and fuel revenue...

Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Down After Earnings Miss

3:39 20-02-2026

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL - Get Free Report)'s stock price gapped down before the...

Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2025 Earnings Call Transcript

11:45 19-02-2026

Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2025 Earnings Call Transcript...

Madrigal (MDGL) Reports Q4 Loss, Beats Revenue Estimates

9:16 19-02-2026

Madrigal (MDGL) came out with a quarterly loss of $2.57 per share versus the Zacks Consensus Estimat...

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results

7:00 19-02-2026

Fourth -quarter and full-year 2025 Rezdiffra ® (resmetirom) net sales of $321.1 million and $958.4 ...

Head-To-Head Review: Madrigal Pharmaceuticals (NASDAQ:MDGL) and Praxsyn (OTCMKTS:PXYN)

1:56 19-02-2026

Praxsyn (OTCMKTS:PXYN - Get Free Report) and Madrigal Pharmaceuticals (NASDAQ: MDGL - Get Free Repor...

Madrigal Pharmaceuticals: What To Expect With Q4 Earnings Coming Thursday

8:15 17-02-2026

Madrigal Pharmaceuticals is reiterated as a Strong Buy ahead of Q4 earnings, with a 12-month price t...

MDGL Strengthens MASH Franchise With New Genetic Approaches

11:41 12-02-2026

Madrigal inks $4.4B siRNA licensing deal with Ribo in $60M upfront pact, adding preclinical candidat...

Madrigal (MDGL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

11:06 12-02-2026

Madrigal (MDGL) doesn't possess the right combination of the two key ingredients for a likely earnin...

Ribo und Ribocure geben exklusive globale Lizenzvereinbarung mit Madrigal für neuartige siRNA-Therapeutika gegen MASH bekannt

5:47 12-02-2026

/PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) („Ribo") und ihre Tochtergesellsc...

Ribo et Ribocure annoncent un accord de licence mondial exclusif avec Madrigal pour de nouvelles thérapies pARNi ciblant la stéatohépatite associée à un dysfonctionnement métabolique (MASH)

5:44 12-02-2026

/PRNewswire/ -- Suzhou Ribo Life Science Co, Ltd. (HKEX: 06938) (« Ribo ») et sa filiale Ribocure ...

Baader Bank Aktiengesellschaft Invests $885,000 in Madrigal Pharmaceuticals, Inc. $MDGL

5:22 12-02-2026

Baader Bank Aktiengesellschaft purchased a new stake in shares of Madrigal Pharmaceuticals, Inc. (NA...

Výsledovka

Rozvaha

Peněžní toky